Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

ClinicalTrials.gov ID: NCT00991289

Public ClinicalTrials.gov record NCT00991289. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection

Study identification

NCT ID
NCT00991289
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
68 participants

Conditions and interventions

Interventions

  • Nitazoxanide (NTZ) Drug
  • Pegylated interferon alfa-2a (PEG) Drug
  • Ribavirin (RBV) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2009
Primary completion
Oct 31, 2010
Completion
Dec 31, 2011
Last update posted
Nov 3, 2021

2010 – 2012

United States locations

U.S. sites
17
U.S. states
10
U.S. cities
15
Facility City State ZIP Site status
Alabama Therapeutics CRS Birmingham Alabama 35294-2050
UCLA CARE Center CRS Los Angeles California 90035
Stanford AIDS Clinical Trials Unit CRS Palo Alto California 94304-5350
UCSD Antiviral Research Center CRS San Diego California 92103
Ucsf Hiv/Aids Crs San Francisco California 94110
Massachusetts General Hospital CRS (MGH CRS) Boston Massachusetts 02114
New Jersey Medical School- Adult Clinical Research Ctr. CRS Newark New Jersey 07103
Weill Cornell Chelsea CRS New York New York 10011
Columbia P&S CRS New York New York 10032
Trillium Health ACTG CRS Rochester New York 14607
Univ. of Rochester ACTG CRS Rochester New York 14642
Chapel Hill CRS Chapel Hill North Carolina 27514
Cincinnati Clinical Research Site Cincinnati Ohio 45267-0405
MetroHealth CRS Cleveland Ohio 44109
Penn Therapeutics, CRS Philadelphia Pennsylvania 19104
The Miriam Hospital Clinical Research Site (TMH CRS) CRS Providence Rhode Island 02906
Virginia Commonwealth Univ. Medical Ctr. CRS Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00991289, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 3, 2021 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00991289 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →